Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Breast Carcinoma
|
2793 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.060 | 1.000 | 6 | 2009 | 2017 | |||||
Malignant neoplasm of breast
|
3417 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.060 | 1.000 | 6 | 2009 | 2017 | |||||
Neoplasm Metastasis
|
327 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.050 | 1.000 | 5 | 2007 | 2013 | |||||
Malignant Neoplasms
|
1641 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.040 | 1.000 | 4 | 2011 | 2018 | |||||
Myocardial Infarction
|
680 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.030 | 0.667 | 3 | 2010 | 2017 | |||||
Primary malignant neoplasm
|
1374 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.030 | 1.000 | 3 | 2011 | 2018 | |||||
Colorectal Carcinoma
|
1962 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.020 | 1.000 | 2 | 2007 | 2018 | |||||
Coronary Artery Disease
|
1577 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.020 | 1.000 | 2 | 2014 | 2015 | |||||
Coronary heart disease
|
1178 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.020 | 0.500 | 2 | 2014 | 2015 | |||||
Liver carcinoma
|
942 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.020 | 1.000 | 2 | 2009 | 2018 | |||||
Lymphoma, Non-Hodgkin
|
197 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.020 | 1.000 | 2 | 2009 | 2018 | |||||
Malignant neoplasm of colon and/or rectum
|
502 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.020 | 1.000 | 2 | 2007 | 2018 | |||||
Neoplasms
|
1644 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.020 | 1.000 | 2 | 2009 | 2011 | |||||
Acute lymphocytic leukemia
|
222 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||
Adult Acute Lymphocytic Leukemia
|
154 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||
Adult Hodgkin Lymphoma
|
27 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2009 | 2009 | |||||
Adult Non-Hodgkin Lymphoma
|
39 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2009 | 2009 | |||||
Cancer of Urinary Tract
|
11 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Childhood Acute Lymphoblastic Leukemia
|
261 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||
Childhood Hodgkin Lymphoma
|
29 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2009 | 2009 | |||||
Childhood Leukemia
|
140 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Childhood Non-Hodgkin Lymphoma
|
39 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2009 | 2009 | |||||
Chronic Lymphocytic Leukemia
|
291 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Coinfection
|
11 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Colon Carcinoma
|
275 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2007 | 2007 |